Functional Evaluation of Factor H genetic and Acquired Abnormalities: Application for Atypical Hemolytic Uremic Syndrome (aHUS)

  • Lubka T. Roumenina
  • Roxane Roquigny
  • Caroline Blanc
  • Nelly Poulain
  • Stéphanie Ngo
  • Marie-Agnès Dragon-Durey
  • Véronique Frémeaux-Bacchi
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1100)

Abstract

The atypical hemolytic uremic syndrome (aHUS) is a paradigm of a disease, caused by overactivation of the alternative complement pathway secondary to a not well-understood trigger event. About 60 % of the patients present genetic or acquired abnormalities in the proteins of the alternative complement pathway. In 40 % of the cases the affected protein is the complement regulator Factor H (FH)—30 % due to mutations and 10 % because of anti-FH autoantibodies. Here we describe the detailed protocol for a rapid test to analyse the functional defect associated with genetic or acquired FH-related abnormalities. It can be applied for the characterization of the underlying complement defect in aHUS, based on spontaneous lysis of non-sensitized sheep erythrocytes in contact with patients’ plasma or serum.

Key words

Complement aHUS C3 Endothelium FH Disease risk Therapy 

References

  1. 1.
    Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA (1998) Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53:836–844PubMedCrossRefGoogle Scholar
  2. 2.
    de Cordoba SR, de Jorge EG (2008) Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 151:1–13PubMedCrossRefGoogle Scholar
  3. 3.
    Nilsson SC, Sim RB, Lea SM, Fremeaux-Bacchi V, Blom AM (2011) Complement factor I in health and disease. Mol Immunol 48:1611–1620PubMedCrossRefGoogle Scholar
  4. 4.
    Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH (2004) Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 41:e84PubMedCrossRefGoogle Scholar
  5. 5.
    Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautes-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V (2010) Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77:339–349PubMedCrossRefGoogle Scholar
  6. 6.
    Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH (2003) Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 100:12966–12971PubMedCrossRefGoogle Scholar
  7. 7.
    Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G (2003) Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362:1542–1547PubMedCrossRefGoogle Scholar
  8. 8.
    Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, Bigot S, Hue C, Satchell SC, Mathieson PW, Mousson C, Noel C, Sautes-Fridman C, Halbwachs-Mecarelli L, Atkinson JP, Lionet A, Fremeaux-Bacchi V (2012) A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119:4182–4191PubMedCrossRefGoogle Scholar
  9. 9.
    Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112:4948–4952PubMedCrossRefGoogle Scholar
  10. 10.
    Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V (2009) Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114:2837–2845PubMedCrossRefGoogle Scholar
  11. 11.
    Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Rodriguez de Cordoba S (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 104:240–245PubMedCrossRefGoogle Scholar
  12. 12.
    Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fremeaux-Bacchi V (2011) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180–2187CrossRefGoogle Scholar
  13. 13.
    Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V (2005) Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555–563PubMedCrossRefGoogle Scholar
  14. 14.
    Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V (2011) Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 365:8–26PubMedCrossRefGoogle Scholar
  15. 15.
    Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687PubMedCrossRefGoogle Scholar
  16. 16.
    Salant DJ (2011) Targeting complement C5 in atypical hemolytic uremic syndrome. J Am Soc Nephrol 22:7–9PubMedCrossRefGoogle Scholar
  17. 17.
    Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey A, Macher MA, Zuber J, karras A, Provost F, Moulin B, Grunfeld JP, Niaudet P, Lesavre P, Fremeaux-Bacchi V (2012) Role of acquired and genetic complement abnormalities in dense deposit disease, glomerulonephritis with isolated C3 deposits, and membranoproliferative glomerulonephritis type I. Kidney Int 82(4):454–464Google Scholar
  18. 18.
    Jokiranta TS, Jaakola VP, Lehtinen MJ, Parepalo M, Meri S, Goldman A (2006) Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J 25:1784–1794PubMedCrossRefGoogle Scholar
  19. 19.
    Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF (2003) Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 111:1181–1190PubMedGoogle Scholar
  20. 20.
    Kazatchkine MD, Fearon DT, Austen KF (1979) Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol 122:75–81PubMedGoogle Scholar
  21. 21.
    Jozsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF (2007) Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110:1516–1518PubMedCrossRefGoogle Scholar
  22. 22.
    Heinen S, Sanchez-Corral P, Jackson MS, Strain L, Goodship JA, Kemp EJ, Skerka C, Jokiranta TS, Meyers K, Wagner E, Robitaille P, Esparza-Gordillo J, Rodriguez de Cordoba S, Zipfel PF, Goodship TH (2006) De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 27:292–293PubMedCrossRefGoogle Scholar
  23. 23.
    Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S, Lopez-Trascasa M (2004) Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 41:81–84PubMedCrossRefGoogle Scholar
  24. 24.
    Stahl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D (2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111:5307–5315PubMedCrossRefGoogle Scholar
  25. 25.
    Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Fremeaux-Bacchi V, Niaudet P (2012) Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 12:1938–1944PubMedCrossRefGoogle Scholar
  26. 26.
    Johnson SA, Williams JM, Hakobyan S, Richards A, Perkins SJ, Marchbank KJ, Goodship TH, Morgan BP, Taylor CM, Savage CO (2010) Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome-A pedigree revisited. Mol Immunol 47:1585–1591PubMedCrossRefGoogle Scholar
  27. 27.
    Ferreira VP, Herbert AP, Cortes C, McKee KA, Blaum BS, Esswein ST, Uhrin D, Barlow PN, Pangburn MK, Kavanagh D (2009) The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 182:7009–7018PubMedCrossRefGoogle Scholar
  28. 28.
    Francis NJ, McNicholas B, Awan A, Waldron M, Reddan D, Sadlier D, Kavanagh D, Strain L, Marchbank KJ, Harris CL, Goodship TH (2012) A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 119:591–601PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Lubka T. Roumenina
    • 1
  • Roxane Roquigny
    • 2
  • Caroline Blanc
    • 1
  • Nelly Poulain
    • 3
  • Stéphanie Ngo
    • 3
  • Marie-Agnès Dragon-Durey
    • 4
    • 5
    • 6
  • Véronique Frémeaux-Bacchi
    • 7
  1. 1.Cordeliers Research Center, INSERM UMRS 872Université Pierre et Marie Curie, and Université Paris DescartesParisFrance
  2. 2.Cordeliers Research CenterUniversité Pierre et Marie Curie, Université Paris DescartesParisFrance
  3. 3.Service d’Immunologie BiologiqueHôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de ParisParisFrance
  4. 4.Cordeliers Research CenterINSERM UMRS 872ParisFrance
  5. 5.Université Paris Descartes, Sorbonne Paris CitéParisFrance
  6. 6.Assitance Publique-Hopitaux de Paris Hopit al Europeen Georges-PompidouService d’Immunologie BiologiqueParis CedexFrance
  7. 7.Assitance Publique-Hopitaux de Paris Hopit al Europeen Georges-PompidouService d’Immunologie Biologique, APHPParisFrance

Personalised recommendations